Industry pushes FDA for tailored complex generics post-approval changes guidance
Regulatory NewsJoanne S. Eglovitch
ComplianceNorth AmericaPharmaceuticalsProduct LifecycleQuality Assurance and ControlRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchComplianceNorth AmericaPharmaceuticalsProduct LifecycleQuality Assurance and ControlRegulatory Intelligence/Policy